Sture Jan-Gunnar Gustafsson

Ceffort AB provides solutions in support for research and development, manufacturing, and business processes. Its common project-based activities includes customer representation; bioprocess development; bioanalytics, sensors, and instrumentation; quality management and documentation; market activities on behalf of customers; due diligence; and competence development. The company was founded by Erik Gunnar Hörnsten in 2009 and is headquartered in Furulund, Sweden.

Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase.